The potential for synergistic combination treatment with the spliceosome inhibitor E7107 and the MDM2–p53 antagonist RG7388 was investigated in leukaemia–lymphoma cell lines and primary CLL samples. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.